Theravance Biopharma Inc
TBPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$873.82M
Close$
$10.75
36.3% downside
Current Fair Value
36.3% downsideOvervalued by 36.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $873.82 Million |
|---|---|
| Enterprise Value | $645.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.1 |
| Beta | 0.17 |
| Outstanding Shares | 51,279,000 |
Return
| Return on Equity | 24.25% |
|---|---|
| Return on Assets | 24.25% |
| Return on Invested Capital | 18.63% |
Valuation & Multiples
| P/E Ratio | 7.45 |
|---|---|
| PEG | -11.7 |
| Price to Sales | 8.44 |
| Price to Book Ratio | 3.38 |
| Enterprise Value to Revenue | 5.88 |
| Enterprise Value to EBIT | 7.86 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$17.78 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$21.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 1191.90% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 5,000▼ 99.15% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.05%▼ 96.64% |
|---|---|
| Total Invested | $9.20M▼ 98.87% |
| Investors Holding | 32▼ 147.00% |
ESG Score
No data
About Theravance Biopharma Inc
CEO: Rick Winningham